Table of Content

Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in viral vector dealmaking



2.1. Introduction

2.2. Viral vector partnering over the years

2.3. Most active viral vector dealmakers

2.4. Viral vector partnering by deal type

2.5. Viral vector partnering by therapy area

2.6. Deal terms for viral vector partnering

2.6.1 Viral vector partnering headline values

2.6.2 Viral vector deal upfront payments

2.6.3 Viral vector deal milestone payments

2.6.4 Viral vector royalty rates



Chapter 3 – Leading viral vector deals



3.1. Introduction

3.2. Top viral vector deals by value



Chapter 4 – Most active viral vector dealmakers



4.1. Introduction

4.2. Most active viral vector dealmakers

4.3. Most active viral vector partnering company profiles



Chapter 5 – Viral vector contracts dealmaking directory



5.1. Introduction

5.2. Viral vector contracts dealmaking directory



Chapter 6 – Viral vector dealmaking by technology type



Appendices



Appendix 1 – Viral vector deals by company A-Z



Appendix 2 – Viral vector deals by stage of development



Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation



Appendix 3 – Viral vector deals by deal type



Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty



Appendix 4 – Viral vector deals by therapy area



Deal type definitions



Further reading on dealmaking



About Wildwood Ventures



Current Partnering

Current Agreements

Recent report titles from Current Partnering



Table of figures



Figure 1: Viral vector partnering since 2016

Figure 2: Active viral vector dealmaking activity since 2016

Figure 3: Viral vector partnering by deal type since 2016

Figure 4: Viral vector partnering by disease type since 2016

Figure 5: Viral vector deals with a headline value

Figure 6: Viral vector deals with an upfront value

Figure 7: Viral vector deals with a milestone value

Figure 8: Viral vector deals with a royalty rate value

Figure 9: Top viral vector deals by value since 2016

Figure 10: Most active viral vector dealmakers since 2016